- Home
- AGEN vs CLNN Comparison
AGEN vs CLNN Comparison
Compare AGEN & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- CLNN
- Stock Information
- Founded
- AGEN 1994
- CLNN 2012
- Country
- AGEN United States
- CLNN United States
- Employees
- AGEN N/A
- CLNN N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- CLNN Health Care
- Exchange
- AGEN Nasdaq
- CLNN Nasdaq
- Market Cap
- AGEN 126.8M
- CLNN 120.6M
- IPO Year
- AGEN 2000
- CLNN N/A
- Fundamental
- Price
- AGEN $4.29
- CLNN $8.82
- Analyst Decision
- AGEN Buy
- CLNN Strong Buy
- Analyst Count
- AGEN 2
- CLNN 6
- Target Price
- AGEN $14.50
- CLNN $32.67
- AVG Volume (30 Days)
- AGEN 460.1K
- CLNN 136.1K
- Earning Date
- AGEN 11-10-2025
- CLNN 11-13-2025
- Dividend Yield
- AGEN N/A
- CLNN N/A
- EPS Growth
- AGEN N/A
- CLNN N/A
- EPS
- AGEN N/A
- CLNN N/A
- Revenue
- AGEN $106,829,000.00
- CLNN $214,000.00
- Revenue This Year
- AGEN $60.49
- CLNN N/A
- Revenue Next Year
- AGEN N/A
- CLNN $1,363.77
- P/E Ratio
- AGEN N/A
- CLNN N/A
- Revenue Growth
- AGEN N/A
- CLNN N/A
- 52 Week Low
- AGEN $1.38
- CLNN $2.28
- 52 Week High
- AGEN $7.34
- CLNN $13.50
- Technical
- Relative Strength Index (RSI)
- AGEN 54.02
- CLNN 48.24
- Support Level
- AGEN $4.17
- CLNN $8.29
- Resistance Level
- AGEN $4.60
- CLNN $8.86
- Average True Range (ATR)
- AGEN 0.28
- CLNN 1.24
- MACD
- AGEN 0.04
- CLNN -0.25
- Stochastic Oscillator
- AGEN 61.32
- CLNN 30.54
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.